A chromatogram analysis tool receives blood test data for a sample and divides the data into regions and determines a best-fit match template for each region. The chromatogram analysis tool determines a best-fit match for each region by comparing the blood test data to a set of templates associated with archetypical shapes of the region. The template with the highest r-squared value for the blood test data is the best-fit template. The chromatogram analysis tool generates a report based on the best-fit match templates for each region, which can indicate medical conditions or recommendations for additional testing.

The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.

Provided are methods of detecting the presence or amount of a vitamin D metabolite in a sample using mass spectrometry. The methods generally directed to ionizing a vitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. Also provided are methods to detect the presence or amount of two or more vitamin D metabolites in a single assay.

At least one stable isotope reagent is added to each biological sample and standard sample to prepare biological samples for analysis and standard sample for analysis. The quality of the biological samples is evaluated using data of one set of biological samples for analysis composed of a plurality of biological samples for analysis. Besides, the quality of a pretreatment and/or analysis of each set of samples for analysis is evaluated using data obtained by analyzing the standard sample for analysis before and after an analysis of one set of samples for analysis. An abnormality in a chromatograph or mass analyzer used for the analysis of one set of samples is evaluated by the data obtained by analyzing a sample for device evaluation before and after the analysis of one set of samples for analysis. Thus, the quality of data obtained by chromatographic mass spectrometry on biological samples is comprehensively evaluated.

A method for preparation of a dried blood sample for multiplexing of analytes includes the steps of mixing an Internal Standard solution with a first diluent in a vessel, the Internal Standard solution including a plurality of different Internal Standards, adding the dried blood sample to the vessel, sonicating the vessel containing the Internal Standard solution, the first diluent and the dried blood sample, and removing the dried blood sample from the vessel. The Internal Standard solution can include a plurality of Internal Standards. The Internal Standard solution can include at least 15 Internal Standards. The dried blood sample can be generated using less than 50 L of blood. The dried blood sample can be generated using less than 10 L of blood. The first diluent can include methanol or a mixture of water and methanol.

A method of producing protein products including alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins from plasma includes steps of: (1) adding a salt to the blood product to produce a first intermediate, wherein the salt comprises between 11-13 wt % of the first intermediate; (2) separating the first intermediate to produce a first supernatant and a first paste; (3) adding a salt to the first intermediate to produce a second intermediate, wherein the salt comprises between 21-23 wt % of the second intermediate; (4) separating the second intermediate to produce a second supernatant and a second paste; (5) separating a third intermediate from the second supernatant by affinity chromatography; and (6) separating the third intermediate by ion exchange chromatography to produce an eluate containing the protein product. Advantageously, the inventive methods are simple and produce alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins in high yields.

Methods and systems for quantifying blood brain barrier (BBB) permeation of glycosylated peptides. The methods and systems feature microdialysis probes and mechanisms for infusing preservative agents into the outflow tubes of the microdialysis probes. The preservative agents help reduce unwanted degradation of the glycosylated peptides or other compounds, which can lead to a more accurate and complete analysis of the outflow tube perfusate.

Disclosed herein are methods, biomarkers, systems, compositions and kits for determining the phase or metabolic state (e.g. First Phase, Second Phase, or Third Phase) of a red blood cell (RBC) sample or for determining the phase or metabolic state (e.g., First Phase or Second Phase) of a platelet (PLT) cell sample. The methods disclosed herein are related to the use of isolated RBC sample or isolated PLT sample and analytical tools for providing information that is relevant to the phase or metabolic state of the RBC sample or the PLT sample. The system disclosed herein utilizes isolated RBC sample or isolated PLT sample and at least one analytical tool or an output from the at least one analytical tool. The compositions and kits described herein utilize RBC samples or PLT samples, including compositions in a form that allows for analysis of the RBC sample or the PLT sample.

Provided is a method for separating and detecting various hemoglobins including abnormal hemoglobins and thalassemia markers. A method for analyzing hemoglobins, comprising separating hemoglobins in a sample by cation exchange chromatography, wherein an eluent having a pH of 8.1 or more and an osmotic pressure of 40 mOsm/kg or less is used for separation of the hemoglobins.

A method of producing protein products including alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins from plasma includes steps of: (1) adding a salt to the blood product to produce a first intermediate, wherein the salt comprises between 11-13 wt % of the first intermediate; (2) separating the first intermediate to produce a first supernatant and a first paste; (3) adding a salt to the first intermediate to produce a second intermediate, wherein the salt comprises between 21-23 wt % of the second intermediate; (4) separating the second intermediate to produce a second supernatant and a second paste; (5) separating a third intermediate from the second supernatant by affinity chromatography; and (6) separating the third intermediate by ion exchange chromatography to produce an eluate containing the protein product. Advantageously, the inventive methods are simple and produce alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins in high yields.